商业化培养基方案|奥浦迈-细胞培养基和端到端CDMO解决方案

OPM-293平台

化学成分确定的基础培养基与高性能补料

OPM-293 瞬时转染系统是化学成分确定的基础培养基与补料组合，专为高效率瞬时转染HEK293细胞株设计开发。该瞬时转染系统支持HEK293细胞的高密度悬浮培养及瞬转。我们针对该系统配备了详尽的使用手册及灵活专业的技术支持。

OPM-293 瞬时转染系统支持高效蛋白质表达，表达量达到克/每升的级别，并且能够应用于腺病毒、腺相关病毒和慢病毒的高效率增殖。此外，OPM-293系列细胞培养基易于放大培养规模，适用于平板、摇瓶、TPP管、Wave及大规模反应器。

产品特点：

化学成分确定，无动物源成分，不含蛋白质或生长因子
支持多种类型的HEK293细胞瞬时转染与稳定转染
支持多种类型的HEK293细胞，用于快速增殖和高密度培养，添加补料后可超过20x10⁶ cells/ml
批间质量稳定
快速、稳定的货期
灵活、专业、省心的售后服务

申请新品试用

产品信息表

产品名称	货号	剂型	规格	类型	SDS	描述
OPM-293 CD03 Medium	81070-001	液体	1000mL	化学成分确定培养基
OPM-293 CD03 DPM	91070-010	干粉	10L	化学成分确定培养基
OPM-293 CD03 DPM	91070-050	干粉	50L	化学成分确定培养基
OPM-293 CD05 Medium	81075-001	液体	1000mL	化学成分确定培养基
OPM-CD Trans293	P82019	液体	1000mL	化学成分确定培养基
OPM-293 ProFeed	F081918	液体	100mL	无蛋白质补料
OPM-293 ProFeed	F081918-001	液体	1000mL	无蛋白质补料

查找CoA

*该页面只支持下载OPM-293系列的CoA文件

使用奥浦迈产品发表的文献

Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2
Adv Sci (Weinh). 2022 Mar 23;e2200063.
Structures of Omicron spike complexes and implications for neutralizing antibody development
Cell Rep. 2022 May 3;39(5):110770.
Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza
J Leukoc Biol. 2022 Jan 17.

使用奥浦迈产品发表的文献

Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2
Adv Sci (Weinh). 2022 Mar 23;e2200063.
Structures of Omicron spike complexes and implications for neutralizing antibody development
Cell Rep. 2022 May 3;39(5):110770.
Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza
J Leukoc Biol. 2022 Jan 17.
Screening of Monoclonal Antibodies Targeting the Equine IgG1 Based on Single B Cell Antibodies Gene Amplification Technology
China Biotechnology. 2022, Vol. 42 Issue (4): 17-23.
Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine
Biorxiv.2022 May.
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
Nat Commun. 2021 Mar 1;12(1):1346.
An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Protein Cell. 2021 Sep 23;1-21.
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
Cell Rep. 2021 Feb 2;34(5):108699.
Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2. 2
Cell Rep. 2021 Nov 2;37(5):109931.
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2
Elife. 2021 Aug 20;10:e69091.
Structure and Function of the Refined C-Terminal Loop in Imidazole Glycerol Phosphate Dehydratase from Different Homologs
J Agric Food Chem. 2021 Nov 24;69(46):13871-13880.
Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma
J Immunother. 2021 Apr 1;44(3):106-113.
Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys
Bioconjug Chem. 2021 May 19;32(5):1034-1046.
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
J Biol Eng. 2021 Jun 29;15(1):18.
Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy
Bioengineered. 2021 Dec;12(1):2095-2105.
Mutation N501Y in RBD of spike protein strengthens the interaction between COVID-19 and its receptor ACE2
Biorxiv. 2021 February 18.
Screening and Identification of a Novel Anti-siglec-15 Human Antibody 3F1 and the Research on Its Antitumor Activity
Papers.SSRN. 2021 Oct.
An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses
Immunol Lett. 2020 Jun;222:29-39.
Establishing 293T suspension cultrue for lentiviral vector production in a stirred bioreactor
Authorea. 2020 November 10.

案例展示

HEK293瞬时转染培养基案例

支持高水平抗体瞬时表达
支持高水平病毒瞬时表达

OPM-CD Trans293 培养基支持重组蛋白或抗体的高水平瞬时表达，最高可达到1000mg/L以上

OPM-CD Trans293 培养基具有优异的批间稳定性

OPM-CD Trans293 培养基支持慢病毒（LV），腺病毒（AdV)以及腺相关病毒(AAV)的高水平瞬时表达。

OPM-CD Trans293+293 ProFeed 培养基与配套的293 ProFeed 补料可将病毒滴度提升50%以上，达到1x10⁷ TU/ml水平

使用 OPM-CD Trans293 培养基，得到的病毒滴度最高，工艺优化前即可达到2.29x10¹⁰ vg/ml水平。经过工艺优化，可以超过1x10¹¹ vg/ml

使用 OPM-CD Trans293 培养基，腺病毒滴度与某进口培养基一致（2x10⁹ IFU/mL）

常见问题

奥浦迈293瞬转的产量一般在多少？
- 一般抗体可以达到(50-300)mg/L。
在使用293 CD05产蛋白后，下游经常出现镍柱掉镍，蛋白不纯的情况，如何考虑改进？
- 可以建议客户使用耐受EDTA的镍柱，如GE 的Ni Excel。
OPM 293培养基可以用于细胞治疗领域吗？
- OPM 293-CD05搭配补料293-ProFeed，可以培养293FT细胞生产慢病毒（LV），慢病毒用于细胞治疗的载体。
293瞬转，客户使用补料293-ProFeed后细胞活率下降快？
- 需要摸索293-ProFeed的浓度，可以尝试分别补加5%，3%，7%。
奥浦迈培养基细菌内毒素控制在什么范围？
- （1)基础培养基控制在＜1.0 EU/ml，(2)补料控制在＜10 EU/ml，(3)超浓缩补料因为pH高，对内毒检测有干扰，所以一般只是作为内控，客户有要求的可以写在COA上，如CDFS08
奥浦迈对CD培养基的定义是什么，包括Insulin和IgF-1吗？
- 我们把胰岛素和IgF-1也定义为CD，但培养基里若含有这些成分，我们会明确告知客户。
补料中是否含有谷氨酰胺？
- 我们的补料中都不含谷氨酰胺；如含有谷氨酰胺，我们会标明。

商业化培养基方案

商业化培养基方案

01

02

03

04

05

Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2

Structures of Omicron spike complexes and implications for neutralizing antibody development

Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza

Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2

Structures of Omicron spike complexes and implications for neutralizing antibody development

Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza

Screening of Monoclonal Antibodies Targeting the Equine IgG1 Based on Single B Cell Antibodies Gene Amplification Technology

Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2. 2

N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2

Structure and Function of the Refined C-Terminal Loop in Imidazole Glycerol Phosphate Dehydratase from Different Homologs

Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma

Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys

Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds

Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy

Mutation N501Y in RBD of spike protein strengthens the interaction between COVID-19 and its receptor ACE2

Screening and Identification of a Novel Anti-siglec-15 Human Antibody 3F1 and the Research on Its Antitumor Activity

An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses

Establishing 293T suspension cultrue for lentiviral vector production in a stirred bioreactor

HEK293瞬时转染培养基案例

快速导航

联系我们

请扫描二维码关注奥浦迈官方公众号

申请新品试用